Cutaneous melanoma

New England Journal of Medicine

Volumn 325, Issue 3, 1991, Pages 171-182

  Koh, Howard K ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCG VACCINE; CISPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNE TRANSFER FACTOR; INTERLEUKIN 2; LEVAMISOLE; TAMOXIFEN;

ADJUVANT THERAPY; BIOPSY; DIFFERENTIAL DIAGNOSIS; DRUG THERAPY; HUMAN; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROPIONIBACTERIUM ACNES; REVIEW; RISK FACTOR; SKIN CANCER; STAGING; SUN EXPOSURE;

EID: 0025820745     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199107183250306     Document Type: Review

References (192)

1. Feldman A.R., Kessler L., Myers M.H., Naughton M.D. The prevalence of cancer: estimates based on the Connecticut Tumor Registry. N Engl J Med 1986; 315:1394-1397
2. Jensen O.M., Bolander A.M. Trends in malignant melanoma of the skin. World Health Stat Q 1980; 33:2-26.
3. Cancer incidence in five continents. Vol. 1. Berlin, Germany: Springer-Verlag, 1966; Vol. 5. Lyon, France: International Agency for Research on Cancer, 1987.
4. National Cancer Institute. Cancer statistics review 1973–1987. Bethesda, Md.: Department of Health and Human Services, 1990. (NIH publication no. 90–2789.)
5. Davis D.L., Hoel D., Fox J., Lopez A. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet 1990; 336:474-481
6. Glass A.G., Hoover R.N. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989; 262:2097-2100
7. Balch C.M., Milton G., eds. Cutaneous melanoma: clinical management and treatment results worldwide. Philadelphia: J.B. Lippincott, 1985.
8. Rigel D.S., Kopf A.W., Friedman R.J. The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol 1987; 17:1050-1053
9. van der Esch E.P., Muir C.S., Nectoux J., et al. Temporal change in diagnostic criteria as a cause of the increase of malignant melanoma over time is unlikely. Int J Cancer 1991; 47:483-489
10. Boring C.C., Squires T.S., Tong T. Cancer statistics, 1991. CA 1991; 41:19-36.
11. Meryman R. Hope — a loss survived. Boston: Little Brown, 1980: 10.
12. Albert V.A., Koh H.K., Geller A.C., Miller D.R., Prout M.N., Lew R.A. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 1990; 23:308-310
13. Rhodes A.R., Weinstock M.A., Fitzpatrick T.B., Mihm M.C. Jr., Sober A.J. Risk factors for cutaneous melanoma. JAMA 1987; 258:3146-3154
14. MacKie R.M., Freudenberger T., Aitchison T.C. Personal risk-factor chart for cutaneous melanoma. Lancet 1989; 2:487-490
15. Evans R.D., Kopf A.W., Lew R.A., et al. Risk factors for the development of malignant melanoma-I: review of case control studies. J Dermatol Surg Oncol 1988; 14:393-408.
16. Duggleby W.F., Stoll H., Priore R.L., Greenwald P., Graham S. A genetic analysis of melanoma — polygenic inheritance as a threshold trait. Am J Epidemiol 1981; 114:63-72.
17. Kopf A.W., Hellman L.J., Rogers G.S., et al. Familial malignant melanoma. JAMA 1986; 256:1915-1919
18. Gellin G.A., Kopf A.W., Garfinkel L. Malignant melanoma: a controlled study of possibly associated factors. Arch Dermatol 1969; 99:43-48
19. Lee J.A.H., Strickland D. Malignant melanoma: social status and outdoor work. Br J Cancer 1980; 41:757-763
20. Green A., Swerdlow A.J. Epidemiology of melanocytic nevi. Epidemiol Rev 1989; 11:204-221
21. Elwood J.M., Gallagher R.P., Hill G.B., Spinelli J.J., Pearson J.C.G., Threlfall W. Pigmentation and skin reaction to sun as risk factors for cutaneous melanoma: Western Canada Melanoma Study. BMJ 1984; 288:99-102.
22. Longstreth J.D., ed. Appendix A. Ultraviolet radiation and melanoma with a special focus on assessing the risks of stratospheric ozone depletion. Vol. 4 of Assessing the risks of trace gases that can modify the stratosphere. Washington, D.C.: Environmental Protection Agency, 1987.
23. Koh H.K., Kligler B.E., Lew R.A. Sunlight and cutaneous malignant melanoma: evidence for and against causation. Photochem Photobiol 1990; 51:765-779
24. Sober A.J. Solar exposure in the etiology of cutaneous melanoma. Photodermatol 1987; 4:23-31.
25. Lew R.A., Sober A.J., Cook N., Marvell R., Fitzpatrick T.B. Sun exposure habits in patients with cutaneous melanoma: a case control study. J Dermatol Surg Oncol 1983; 9:981-986
26. Armstrong B.K. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun. J Dermatol Surg Oncol 1988; 14:835-849
27. Holman C.D.J., Armstrong B.K., Heenan P.J. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 1986; 76:403-414
28. Kraemer K.H., Lee M.M., Scotto J. Xeroderma pigmentosum: cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123:241-250
29. Ley R.D., Applegate L.A., Padilla R.S., Stuart T.D. Ultraviolet radiation —induced malignant melanoma in Monodelphis domestica. Photochem Photobiol 1989; 50:1-5.
30. Molina M.J., Rowland F.S. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature 1974; 249:810-812
31. Bowman K.P. Global trends in total ozone. Science 1988; 239:48-50.
32. Swerdlow A.J., English J.S., MacKie R.M. Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ 1988; 297:647-649
33. Walter S.D., Marrett L.D., From L., Hertzman C., Shannon H.S., Roy P. The association of cutaneous malignant melanoma with the use of sunbeds and sunlamps. Am J Epidemiol 1990; 131:232-243
34. Fitzpatrick T.B., Szabo G. The melanocyte: cytology and cytochemistry. J Invest Dermatol 1959; 32:197-209.
35. Gilchrest B.A., Treloar V., Grassi A.M., Yaar M., Szabo G., Flynn E. Characteristics of cultivated adult human nevocellular nevus cells. J Invest Dermatol 1986; 87:102-107
36. Herlyn M., Clark W.H., Rodeck U., Mancianti M.L., Jambrosic J., Koprowski H. Biology of tumor progression in human melanocytes. Lab Invest 1987; 56:461-474
37. Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J. Surface antigens of melanocytes and melanomas: markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982; 156:1755-1766
38. Thomson T.M., Real F.X., Murakami S., Cordon-Cardo C., Old L.J., Houghton A.N. Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies, J Invest Dermatol 1988; 90:459-466
39. Herlyn M., Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol 1988; 6:283-308.
40. Ellis D.L., Kafka S.P., Chow J.C., et al. Melanoma, growth factors, acanthosis nigricans, the sign of Leser—Trélat, and the multiple acrochordons: a possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 1987; 317:1582-1587
41. Halaban R., Ghosh S., Baird A. bFGF is the putative natural growth factor for human melanocytes. In Vitro Cell Dev Biol 1987; 23:47-52.
42. Balaban G., Herlyn M., Guerry D. IV, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 1984; 11:429-439
43. Bale S.J., Dracopoli N.C., Tucker M.A., et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320:1367-1372
44. Trent J.M., Meyskens F.L., Salmon S.E., et al. Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med 1990; 322:1508-1511
45. Wittbrodt J., Adam D., Malitschek B., et al. Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus. Nature 1989; 341:415-421
46. Albino A.P., Nanus D.M., Mentle I.R., et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989; 4:1363-1374
47. Elder D.E., Greene M.H. Bondi EE, Clark WH. Acquired melanocytic nevi and melanoma: the dysplastic nevus syndrome. In: Ackerman AB, ed. Pathology of malignant melanoma. New York: Masson, 1981: 185-215.
48. Gown A.M., Vogel A.M., Hoak D., Gough F., McNutt M.A. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986; 123:195-203.
49. Thomson W., MacKie R.M. Comparison of five antimelanoma antibodies for identification of melanocytic cells on tissue sections in routine dermatopathology. J Am Acad Dermatol 1989; 21:1280-1284
50. Cochran A.J., Wen D.R., Herschman H.R., Gaynor R.B. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982; 30:295-297
51. Sober A.J., Fitzpatrick T.B., Mihm M.C., et al. Early recognition of cutaneous melanoma. JAMA 1979; 242:2795-2799
52. Davis N. Modern concepts of melanoma and its management. Ann Plast Surg 1978; 1:628-629
53. Clark W.H. Jr., From L., Bernardino E.A., Mihm M.C. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-727
54. Koh H.K. When to refer the patient with a pigmented lesion. Hosp Pract [Off] 1986; 21(10A):47-54.
55. Koh H.K., Michalik E., Sober A.J., et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984; 2:994-1001.
56. Weinstock M.A., Sober A.J. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116:303-310
57. Mihm M.C. Jr., Clark W.H. Jr., From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med 1971; 284:1078-1082
58. Krementz E.T., Reed R.J., Coleman W.P. III, Sutherland C.M., Carter R.D., Campbell M. Acral lentiginous melanoma: a clinicopathologic entity. Ann Surg 1982; 195:632-645
59. Nicholls E.M. Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 1973; 32:191-195
60. Pack G., Lenson N., Gerber D. Regional distribution of moles and melanomas. Arch Surg 1952; 65:862-870
61. Rhodes A.R. Melanocytic precursors of cutaneous melanoma. Med Clin North Am 1986; 70:3-37.
62. Clark W.H. Jr., Reimer R.R., Greene M., Ainsworth A.M., Mastrangelo M.J. Origin of familial malignant melanomas from heritable melanocytic lesions: “the B-K mole syndrome”. Arch Dermatol 1978; 114:732-738
63. Greene M.H., Clark W.H. Jr., Tucker M.A., et al. Acquired precursors of cutaneous malignant melanoma: the familial dysplastic nevus syndrome. N Engl J Med 1985; 312:91-97
64. Lynch H.T., Frichot B.C. III, Lynch J.F. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352-356
65. Greene M.H., Clark W.H. Jr., Tucker M.A., Kraemer K.H., Elder D.E. Fraser MC High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102:458-465
66. Kraemer K., Greene M., Tarone R., Elder D.E., Clark W.H. Jr., Guerry D. IV. Dysplastic naevi and cutaneous melanoma risk. Lancet 1983; 2:1076-1077
67. Rigel D.S., Rivers J.K., Kopf A.W., et al. Dysplastic nevi: markers for increased risk for melanoma. Cancer 1989; 63:386-389
68. Piepkorn M., Meyer L.J., Goldgar D., et al. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol 1989; 20:407-415
69. Ackerman A.B. Pathobabel: confusing terminology in the language of melanocytic neoplasia. In: Cascinelli N, Santinami M, Veronesi U, eds. Cutaneous melanoma biology and management. Milan, Italy: Masson, 1990: 127-32.
70. Clemente C., Cochran A.J., Elder D.E., et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol 1991; 22:313-319
71. Lorentzen M., Pers M., Bretteville-Jensen G. The incidence of malignant transformation in giant pigmented nevi. Scand J Plast Reconstr Surg 1977; 11:163-167
72. Rhodes A.R., Melski J.W. Small congenital nevocellular nevi and the risk of cutaneous melanoma. J Pediatr 1982; 100:219-224
73. Rhodes A.R., Silverman R.A., Harrist T.J., Melski J.W. A histologic comparison of congenital and acquired nevomelanocytic nevi. Arch Dermatol 1985; 121:1266-73
74. Melanoma of the skin (excluding eyelid). In: Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott, 1988: 139-44.
75. Iscoe N., Kersey P., Gapski J., et al. Predictive value of staging investigations in patients with clinical stage I malignant melanoma. Plast Reconstr Surg 1987; 80:233-239
76. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-908
77. Breslow. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975; 182:572-575
78. Day C.L. Jr., Mihm M.C. Jr., Lew R.A., Kopf A.W., Sober A.J., Fitzpatrick T.B. Cutaneous malignant melanoma: prognostic guidelines for physicians and patients. CA 1982; 32:113-122
79. Vollmer R.T. Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Annu 1989; 24:383-407.
80. Balch C.M., Soong S.J., Milton G.W., et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 1982; 196:677-684
81. WHO Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma. Prognosis of stage 1 melanoma of the skin. Int J Cancer 1980; 26:733-739
82. Schmoeckel C., Bockelbrink A., Bockelbrink H., Koutsis J., Braun-Falco O. Low- and high-risk malignant melanoma — I. Evaluation of clinical and histological prognosticators in 585 cases. Eur J Cancer Clin Oncol 1983; 19:227-235
83. Thorn M., Adami H.O., Ringborg U., Bergstrom R., Krusemo U. The association between anatomic site and survival in malignant melanoma: an analysis of 12,353 cases from the Swedish Cancer Registry. Eur J Cancer Clin Oncol 1989; 25:483-491
84. Lemish W.M., Heenan P.J., Holman C.D.J., Armstrong B.K. Survival from preinvasive and invasive malignant melanoma in Western Australia. Cancer 1983; 52:580-585
85. Elder D.E., Clark W.H. Jr. Tumor progression and prognosis in malignant melanoma. In: Elder DE, ed. Pathobiology of malignant melanoma. Vol. 8 of Pigment cell. Basel, Switzerland: Karger, 1987: 51-80.
86. Sagebiel R.W. The dysplastic melanocytic nevus. J Am Acad Dermatol 1989; 20:496-501.
87. Rogers G.S., Kopf A.W., Rigel D.S., et al. Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch Dermatol 1983; 119:644-649
88. Day C.L. Jr., Sober A.J., Kopf A.W., et al. A prognostic model for clinical stage I melanoma of the upper extremity: the importance of anatomic subsites in predicting recurrent disease. Ann Surg 1981; 193:436-440
89. Harrist T.J., Rigel D.S., Day C.L. Jr., et al. “Microscopic satellites” are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 1984; 53:2183-2187
90. Kopf A.W., Gross D.F., Rogers G.S., et al. Prognostic index for malignant melanoma. Cancer 1987; 59:1236-1241
91. Balch C.M., Wilkerson J.A., Murad T.M., Soong S.J., Ingalls A.L., Maddox W.A. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980; 45:3012-3017
92. Sorensen F.B. Objective histopathologic grading of cutaneous malignant melanomas by stereologic estimation of nuclear volume. Cancer 1989; 63:1784-1798
93. Clark W.H. Jr., Elder D.E., Guerry D. IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-1904
94. Kheir S.M., Bines S.D., Vonroenn J.M., Soong S.J., Urist M.M., Coon J.S. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg 1988; 207:455-461
95. Ackerman A.B. Malignant melanoma: a unifying concept. Am J Dermatopathol 1980; 2:309-313
96. Cascinelli N., Vaglini M., Nava M., et al. Prognosis of skin melanoma with regional node metastases (stage II). J Surg Oncol 1984; 25:240-247
97. Balch C.M., Soong S.J., Murad T.M., Ingalls A.L., Maddox W.A. A multifactorial analysis of melanoma. III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193:377-388
98. Balch C.M., Soong S.J., Murad T.M., Smith J.W., Maddox W.A., Durant J.R. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1:126-134
99. Presant C.A., Bartolucci A.A. Prognostic factors in metastatic malignant melanoma: the Southeastern Cancer Study Group experience. Cancer 1982; 49:2192-2196
100. Choi K.N., Withers H.R., Rotman M. Intracranial metastases from melanoma: clinical features and treatment by accelerated fractionation. Cancer 1985; 56:1-9.
101. Veronesi U., Cascinelli N., Adamus J., et al. Thin Stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159-1162
102. Veronesi U., Cascinelli N. Narrow excision (1-cm margin). Arch Surg 1991; 126:438-441
103. Breslow A., Macht S.D. Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet 1977; 145:691-692
104. Urist M.M., Balch C.M., Soong S.J., Shaw H.M., Milton G.W., Maddox W.A. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985; 55:1398-1402
105. Elder D.E., Guerry D. IV, Heiberger R.M., et al. Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg 1983; 71:66-72.
106. Balch C.M. Excising melanomas: how wide is enough? And how to reconstruct? J Surg Oncol 1990; 44:135-137
107. Ho V.C., Sober A.J. Therapy for cutaneous melanoma: an update. J Am Acad Dermatol 1990; 22:159-176
108. Cascinelli N., Fontana V., Cataldo I., Balzarini G.P. Multiple primary melanoma. Tumori 1975; 61:481-486
109. Rogers G.S., Kopf A.W., Rigel D., Friedman R.J., Levenstein M., Bart R.S. Hazard-rate analysis in stage I malignant melanoma. Arch Dermatol 1986; 122:999-1102.
110. Day C.L. Jr., Sober A.J., Lew R.A., et al. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 1981; 47:955-962
111. Koh H.K., Sober A.J., Day C.L., et al. Prognosis of clinical stage I melanoma patients with positive elective regional node dissection. J Clin Oncol 1986; 4:1238-1244
112. McCarthy W.H., Shaw H.M., Milton G.W. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 1985; 161:575-580
113. Goldsmith H.S., Shah J.P., Kim D.H. Prognostic significance of lymph node dissection in the treatment of malignant melanoma. Cancer 1970; 26:606-609
114. Balch C.M. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988; 6:163-172
115. Roses D.F., Provet J.A., Harris M.N., Gumport S.L., Dubin N. Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg 1985; 201:103-107
116. Cohen M.H., Ketcham A.S., Felix E.L., et al. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma. Ann Surg 1977; 186:635-642
117. Roses D.F., Harris M.N., Gumport S.L., Michelassi F., Coffey J.A., Dubin N. Regional lymph node dissection for malignant melanoma of the extremities. Surgery 1981; 89:654-659
118. Sim F.H., Taylor W.F., Pritchard D.J., Soule E.H. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986; 61:697-705.
119. Veronesi U., Adamus J., Bandiera D.C., et al. Inefficacy of immediate node dissection in Stage 1 melanoma of the limbs. N Engl J Med 1977; 297:627-630
120. Veronesi. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982; 49:2420-2430
121. Cady B. “Prophylactic” lymph node dissection in melanoma: does it help? J Clin Oncol 1988; 6:2-4.
122. Koh H.K., Sober A.J., Harmon D.C., Lew R.A., Carey R.W. Adjuvant therapy of cutaneous malignant melanoma: a critical review. Med Pediatr Oncol 1985; 13:244-260
123. Eilber F.R., Morton D.L., Holmes E.C., Sparks F.C., Ramming K.P. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med 1976; 294:237-240
124. Veronesi U., Adamus J., Aubert C., et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913-916
125. Franklin H.R., Schraffordt Koops H., Oldhoff J., et al. To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 1988; 6:701-708
126. Cumberlin R., DeMoss E., Lassus M., Friedman M. Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 1985; 3:1022-1031
127. Spitler L.E. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma J Clin Oncol 1991; 9:736-740
128. Quirt I.C., Shelley W.E., Pater J.L., et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991; 9:729-735
129. Wallack M.C., Bash J., Bartolucci A. Improvement in disease-free survival of melanoma patients in conjunction with serologic response in a phase Ia/Ib Southeastern Cancer Study Group trial of vaccinia melanoma oncolysate. Am Surg 1989; 55:243-247
130. Bystryn J.C., Oratz R., Harris M.N., Roses D.F., Golomb F.M., Speyer J.L. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 1988; 61:1065-1070
131. Creagan E.T. Regional and systemic strategies for metastatic malignant melanoma. Mayo Clin Proc 1989; 64:852-860
132. Hill G.J. II, Krementz E.T., Hill H.Z. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer 1984; 53:1299-1305
133. Ghussen F., Nagel K., Groth W., Muller J.M., Stutzer H. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg 1984; 200:764-768
134. Ghussen F., Kruger I., Groth W., Stutzer H. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 1988; 61:654-659
135. Krementz E.T., Carder R.D., Sutherland C.M., Campbell M. The use of regional chemotherapy in the management of malignant melanoma. World J Surg 1979; 3:289-304.
136. Stehlin J.S. Jr., Giovanella B.C., de Ipolyi P.D., Anderson R.F. Eleven years#x0027; experience with hyperthermic perfusion for melanoma of the extremities. World J Surg 1979; 3:305-307
137. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys 1986; 12:867-872
138. Ziegler J.C., Cooper J.S. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys 1986; 12:1839-1842
139. Overett T.K., Shiu M.H. Surgical treatment of distant metastatic melanoma. Cancer 1985; 56:1222-1230
140. Shea T.C., Antman K.H., Eder J.P., et al. Malignant melanoma: treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol 1988; 124:878-884
141. Wolff S.N., Herzig R.H., Fay J.W., et al. High-dose thiotepa with autologous bone marrow transplantation for metastatic melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 1989; 7:245-249
142. Brandt S.J., Peters W.P., Atwater S.K., et al. Effect of recombinant human granulocytemacrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318:869-876
143. Creagan E.T., Ahmann D.L., Frytak S., Long H.J., Itri L.M. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma: analysis of complete and long-term responding patients. Cancer 1986; 58:2576-2578
144. Legha S.S., Papadopoulos N.E.J., Plager C., et al. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 1987; 5:1240-1246
145. Erratum, J Clin Oncol 1987; 5:1858.
146. Kirkwood J.M., Ernstoff M.S., Davis C.A., Reiss M., Ferraresi R., Rudnick S.A. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 1985; 103:32-36
147. McClay E.F., Mastrangelo M.J., Sprandio J.D., Bellet R.E., Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63:1292-1295
148. Vadhan-Raj S., Cordon-Cardo C., Carswell E., et al. Phase I trial of a mouse monoclonal antibody against GD3 gangiioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6:1636-1648
149. Mitchell M.S., Harel W., Kempf R.A., et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990; 8:856-869
150. Berd D., Maguire H.C. Jr., McCue P., Mastrangelo M.J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8:1858-1867
151. Spitler L.E., del Rio M., Khentigan A., et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 1987; 47:1717-1723
152. Murphy J.R., Bishai W., Borowski M., Miyanohara A., Boyd J., Nagle S. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci U S A 1986; 83:8258-8262
153. Jacquillat C., Khayat D., Banzet P., et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66:1873-1878
154. Mishima Y., Honda C., Ichihashi M., et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet 1989; 11:388-389
155. Wick M.M. Therapeutic effect of dopamine infusion on human malignant melanoma. Cancer Treat Rep 1982; 66:1657-1659
156. Creagan E.T., Long H.J., Ahmann D.L., Green S.J. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. Am J Clin Oncol 1984; 7:543-544
157. Croghan M.K., Booth A., Meyskens F.L. Jr. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma. J Biol Response Mod 1988; 7:409-415
158. Goodman G.E., Beaumier P., Hellstrom I., Fernyhough B., Hellstrom K.E. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985; 3:340-352
159. Levine N., Meyskens F.L. Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. Lancet 1980; 2:224-226
160. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210:474-485
161. Nathanson L. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. In: Lewison EF, ed. Conference on spontaneous regression of cancer. National Cancer institute monograph 44. Washington, D.C.: Government Printing Office, 1976: 67-76.
162. Rosenberg S.A., Lotze M.T., Muul L.M., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-897
163. Cascinelli N., Belli F., Marchini S., et al. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients. Tumori 1989; 75:233-244
164. Parkinson D.R., Abrams J.S., Wiernik P.H., et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990; 8:1650-1656
165. West W.H., Tauer K.W., Yannelli J.R., et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905.
166. Rosenberg S.A., Lotze M.T., Yang J.C., et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7:1863-1874
167. Mitchell M.S., Kempf R.A., Harel W., et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988; 6:409-424
168. Erratum, J Clin Oncol 1988; 6:1067.
169. Dillman R.O., Oldham R.K., Barth N.M., Birch R., Arnold J., West W.H. Recombinant interleukin-2 and adoptive immunotherapy alternated with Dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 1990; 82:1345-1349
170. Rosenberg S.A., Packard B.S., Aebersold P.M., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988; 319:1676-80
171. Kradin R.L., Kurnick J.T., Lazarus D.S., et al. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989; 1:577-580
172. Topalian S.L., Solomon D., Avis F.P., et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6:839-853
173. Rosenberg S.A., Aebersold P., Cornetta K., et al. Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323:570-578
174. Koh H.K., Lew R.A., Prout M.N. Screening for melanoma/skin cancer: theoretic and practical considerations. J Am Acad Dermatol 1989; 20: 159-72.
175. Weary P.E. A two-year experience with a series of rural skin and oral cancer detection clinics. JAMA 1971; 217:1862-1863
176. Koh H.K., Geller A.C., Miller D.R., Lew R.A. Can screening for melanoma/ skin cancer save lives? Dermatol Clin (in press).
177. Koh H.K., Caruso A., Gage I., et al. Evaluation of melanoma/skin cancer screening in Massachusetts: preliminary results. Cancer 1990; 65:375-379
178. Rigel D.S., Friedman R.J., Kopf A.W., et al. Importance of complete cutaneous examination for the detection of malignant melanoma. J Am Acad Dermatol 1986; 14:857-860
179. Miller A.B., Chamberlain J., Day N.E., Hakama M., Prorok P.C. Report on a Workshop of the UICC Project on Evaluation of Screening for Cancer. Int J Cancer 1990; 46:761-769
180. Hayward R.S., Steinberg E.P., Ford D.E., Roizen M.F., Roach K.W. Preventive care guidelines: 1991. Ann Intern Med 1991; 114:758-783
181. Screening for skin cancer. In: Preventive Services Task Force. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Baltimore: Williams & Wilkins, 1989: 71-6.
182. American Cancer Society: ACS report on cancer-related health checkup. CA 1980; 30:194-240.
183. Cassileth B.R., Clark W.H. Jr., Lusk E.J., Frederick B.E., Thompson C.J., Walsh W.P. How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol 1986; 14:555-560
184. Marks R., Hill D. Behavioural change in adolescence: a major challenge for skin-cancer control in Australia. Med J Aust 1988; 149:514-515
185. Doherty V.R., MacKie R.M. Experience of a public education programme on early detection of cutaneous malignant melanoma. BMJ 1988; 297:388-391
186. Bonett A., Roder D., Esterman A. Epidemiologic features of melanoma in South Australia: implications for cancer control. Med J Aust 1989; 151:502-509
187. Kopf A., Rivers J., Friedman R., Rigel D., Heilman E. Dysplastic nevi. In: Friedman R. Rigel D, Kopf A, Harris M, Baker D. eds. Cancer of the skin. Philadelphia: W.B. Saunders, 1991.
188. Slue W., Kopf A.W., Rivers J.K. Total-body photographs of dysplastic nevi. Arch Dermatol 1988; 124:1239-1243
189. Vasen H.F.A., Bergman W., van Haeringen A., Scheffer E., van Slooten E.A. The familial dysplastic nevus syndrome: natural history and the impact of screening on prognosis: a study of nine families in the Netherlands. Eur J Cancer Clin Oncol 1989; 25:337-341
190. Friedman R.J., Rigel D.S., Kopf A.W. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA 1985; 35:130-151
191. Alper J.C. Congenital nevi: the controversy rages on. Arch Dermatol 1985; 121:734-735
192. Grossman D.J. Public and professional educational materials on skin cancer. J Am Acad Dermatol 1989; 21:1012-1018